Keytruda (Pembrolizumab) PD-1 Immunotherapy
Authentic Merck-supplied Keytruda (pembrolizumab) at China's top oncology centers. $2,800-$4,500 per cycle vs $11,000+ US — same product, same potency, NMPA-approved channels.
Why China for Keytruda (Pembrolizumab) PD-1 Immunotherapy
50-70% lower per-cycle cost vs USA, same Merck-authentic Keytruda via NMPA-approved channels. $2,800-$4,500/cycle at top National Cancer Centers vs $11,000+ US. First infusion within 5-7 days of arrival. 2-year total savings often exceed $200,000.
Recommended Hospitals for Keytruda (Pembrolizumab) PD-1 Immunotherapy
Hand-picked by case volume, outcomes, and international patient experience.
About Keytruda (Pembrolizumab) PD-1 Immunotherapy
- Multiple solid tumors covered: NSCLC, melanoma, HCC, MSI-H, head-neck, cervical, gastric, esophageal
- PD-L1 expression testing recommended before therapy
- Eligibility confirmed against current NMPA label
Evidence & Reference Standards
Our oncology pathways align with internationally recognized cancer-care guidelines:
SSAnkang Health is a medical-tourism coordination service; clinical procedures are performed by JCI-accredited Chinese hospitals. This page is for general information and does not constitute medical advice.